Valorization of pharmaceutical innovation
(Research conducted by Prof. Gérard de Pouvourville)

In most developed countries that benefit from broad social cover, there is growing discrepancy between healthcare expenditures and public financial capacities. New solutions need to be thought up in order to manage tensions between, on the one hand, the public powers' concern to maintain the solvency of a universal health insurance system that guarantees a high level of healthcare and access to therapeutic innovation for the wider population, and on the other hand, the continuation of an industrial innovation dynamic requiring increasing means. The research program consists in analyzing the processes and payers' decision criteria regarding valorization of pharmaceutical innovation as well as pricing and reimbursement decisions. This analysis is conducted on six major European markets: France, Germany, Italy, Spain, Sweden and the United-Kingdom.